Trichiasis as a result of docetaxel chemotherapy for metastatic prostate cancer (CROSBI ID 662108)
Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija
Podaci o odgovornosti
Raguž, Jelena ; Vuković, Petra ; Marinčić, Iva ; Vincelj, Nikolina ; Krstić, Chiara ; Žepić, Monika ; Šahbazović, Ana ; Šeparović, Robert
engleski
Trichiasis as a result of docetaxel chemotherapy for metastatic prostate cancer
Docetaxel is a chemotherapeutic agent from tihe class of taxanes which works by disrupting microtubule function to inhibit cell division. Docetaxel has been proven as a potent agent in treatment of various solid malignancies, including metastatic prostate cancer. Most adverse events associated with the use of docetaxel have been well documented and are expected, alopecia beeing at the top of the list. Patients are informed to expect not only hair loss, but also loss of ovearll body hair, including eyebrows and eyelashes. Trichiasis is an eyelid abnormality in which the eyelashes are misdirected and grow inwards toward the eye. Those inward-turning lashes rub against the cornea the inner surface of the eyelids which leads to eye irritation, swelling and redness and in severe cases to scarring of the cornea and vision impairment. A 62-year old male with no previous comorbidities was diagnosed with prostate cancer after a routine screeing discovered elevated PSA 14, 6. After biopsy and imaging the patient was classifi ed as intermediate risk based upon his Gleason score 7 (4+3), and PSA level and underwent radical prostatectomy. PHD was adenocarcinoma, GS7, meta lymphonodi, pT3bpN1M0. After surgery the patient received adjuvant radiotherapy in combination with ADT that lasted for 3 years. In 4/2011 the patient underwent orchidectomy on the count of biochemical relaps of the disease. He continued with ADT, Kalufar 5 mg. The patient was stabile untill 7/2014 when the PSA levels begin to rise, although he had no symptoms and was in overall good health. In 10/2014 PSA was 32, 6 and imaging methods (CT and PET scan) showed multiple metatstic lymph nodes and multidisciplinary team suggested chomotherapy with docetaxel which he started in11/2014 and completed in 7/2015. After 2 cycles of chemotherapy the patient lost most of his hair, including eyelashes wich didn’t grow back during the 10 cycles of docetaxel he received. 6-8 weeks after completing chemotherapy the patient started complaining of eye iritation, extensive lacrimation and blurred vison, especially on the left eye. He went for an ophtalmological exam and the diagnosis was trichiasis l. sin et dex susp. The ophtalmologist recommended the patient do eyelash epilation and ordered a checkup 4 weeks later to confi rm the diagnosis. After the confi rmation, the patient continued with mechanical eyelash epilation every 2-3 months. On the last checkup in 12/2016 the ophtalmologist suggested electroepilation as a permanent solution. Although docetaxel has been reported to cause itching, puffi ness, or swelling of the eyelids and loss of eyelashes is very common among patients recieveng this chemotherapy, this specifi c side effect has not been seen among our patients. It is important to keep in mind that chometherapeutics can cause signifi cant impairment in quality of life long after their last dose has been applied.
docetaxel, side-effects, trichiasis, metastatic prostate cancer
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
70-70.
2017.
nije evidentirano
objavljeno
Podaci o matičnoj publikaciji
Libri oncologici : Croatian journal of oncology
Vrdoljak, Danko Velimir ; Vrbanec, Damir ; Tečić Vuger, Ana
Zagreb: Klinički bolnički centar Sestre milosrdnice
0300-8142
Podaci o skupu
1st regional congress of medical oncology and 1st regional congress of oncology pharmacy
poster
04.05.2017-07.05.2017
Dubrovnik, Hrvatska